Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Minori Koshiji Rosales"'
Autor:
Philip J. Gold, Jan K Davidson-Moncada, Keun-Wook Lee, Yeul Hong Kim, Jon M. Wigginton, Minori Koshiji Rosales, Se Hoon Park, Rosalyn A. Juergens, Haeseong Park, Hope E. Uronis, Cheng Ean Chee, Yee Chao, Daniel V.T. Catenacci, Aleksandra Franovic, Yoon-Koo Kang, Jeffrey L. Nordstrom, Kristen A. Marrone, Eun-Kee Song, Jill Lacy, Sunnie Kim, Johanna C. Bendell, Sang Cheul Oh, Matthew C.H. Ng, Ronan J. Kelly, Jennifer Yen, Jong Gwang Kim, Keith L. Knutson, Yung-Jue Bang, A. Craig Lockhart, Howard S. Hochster, Daner Li, Thierry Alcindor, Sun Jin Sym, Peter C. Enzinger
Publikováno v:
The Lancet Oncology. 21:1066-1076
Summary Background Margetuximab, a novel, investigational, Fc-engineered, anti-HER2 monoclonal antibody, is designed to more effectively potentiate innate immunity than trastuzumab. We aimed to evaluate the safety, tolerability, and antitumour activi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2357b7a846f3a40ed58d8a051fe70a90
https://doi.org/10.1016/s1470-2045(20)30326-0
https://doi.org/10.1016/s1470-2045(20)30326-0
Autor:
Harry H. Yoon, Markus Moehler, Daniel V.T. Catenacci, Minori Koshiji Rosales, Yoon-Koo Kang, Lin Shen, Hyun Cheol Chung
Publikováno v:
Journal of Clinical Oncology. 39:TPS264-TPS264
TPS264 Background: Trastuzumab (T), a monoclonal antibody (mAb) targeting HER2, is standard of care 1st-line therapy for advanced HER2+ GEJ/GC patients. M, an investigational Fc-engineered anti-HER2 mAb, targets the same HER2 epitope but with higher
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f9111b77f8b15e7c463521399b9cc8f
https://doi.org/10.1200/jco.2021.39.3_suppl.tps264
https://doi.org/10.1200/jco.2021.39.3_suppl.tps264
Autor:
Daniel V.T. Catenacci, Jon M. Wigginton, Markus Moehler, Hyun Cheol Chung, Yoon-Koo Kang, Harry H. Yoon, Minori Koshiji Rosales, Lin Shen
Publikováno v:
Journal of Clinical Oncology. 38:TPS468-TPS468
TPS468 Background: Trastuzumab (T), a monoclonal antibody (mAb) targeting HER2, is standard of care palliative 1st-line therapy for advanced HER2+ GEJ/GC patients (pts). M, an Fc-engineered anti-HER2 mAb, targets the same HER2 epitope but with higher
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c68d3adb4521de68f0ea930729bd2881
https://doi.org/10.1200/jco.2020.38.4_suppl.tps468
https://doi.org/10.1200/jco.2020.38.4_suppl.tps468
Autor:
Kei Muro, Marcelo Garrido, Philip A. Philip, Minori Koshiji Rosales, Shadia I. Jalal, Manish A. Shah, Toshihiko Doi, Jonathan Bleeker, Weijing Sun, Manuela Machado, Talia Golan, Mario Mandalà, Peter C. Enzinger, Charles S. Fuchs, Atsushi Ohtsu, Taroh Satoh, Yung-Jue Bang, Andrew H. Ko, Diane Levitan, Geoffrey Y. Ku, Kohei Shitara, Raymond Jang, Ravit Geva, Zev A. Wainberg, Rita P. Dalal, Daniel V.T. Catenacci, Harry H. Yoon, Jiangdian Wang, Jean Phillipe Metges
Importance Therapeutic options are needed for patients with advanced gastric cancer whose disease has progressed after 2 or more lines of therapy. Objective To evaluate the safety and efficacy of pembrolizumab in a cohort of patients with previously
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d26009b0c1b72ab0975e356498d81dde
http://hdl.handle.net/11391/1480975
http://hdl.handle.net/11391/1480975
Autor:
Takayuki Yoshino, Minori Koshiji Rosales, Dung T. Le, Luis A. Diaz, Thierry André, Dirk Jäger, Johanna C. Bendell, Bao Lam, S. Peter Kang
Publikováno v:
Journal of Clinical Oncology. 36:TPS877-TPS877
TPS877 Background: Approximately 5% of mCRCs are dMMR, leading to high levels of MSI. CRCs with MSI-H have abundant lymphocyte infiltrates and strong expression of immune checkpoints. In the phase 2 KEYNOTE-016 study, the anti–programmed death 1 (P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bbac3461e13bca7a6b896a0d85188a5c
https://doi.org/10.1200/jco.2018.36.4_suppl.tps877
https://doi.org/10.1200/jco.2018.36.4_suppl.tps877